Corynebacterium striatum: Difference between revisions
From IDWiki
Corynebacterium striatum
No edit summary |
mNo edit summary |
||
| Line 4: | Line 4: | ||
*Only reliably susceptible to [[vancomycin]], [[daptomycin]], and [[linezolid]] (essentially 100% susceptibility)[[CiteRef::neemuchwala2018in]] |
*Only reliably susceptible to [[vancomycin]], [[daptomycin]], and [[linezolid]] (essentially 100% susceptibility)[[CiteRef::neemuchwala2018in]] |
||
| − | **Next-best oral option is [[tetracycline]], but only has 35% susceptibility |
+ | **Next-best oral option is [[tetracycline]], but only has 35% susceptibility, or [[co-trimoxazole]] (similar susceptibility) |
**Other options include [[quinupristin-dalfopristin]] (100%), [[aminoglycosides]] (93%), and [[rifampin]] (85%) |
**Other options include [[quinupristin-dalfopristin]] (100%), [[aminoglycosides]] (93%), and [[rifampin]] (85%) |
||
Latest revision as of 11:56, 9 September 2022
Management
- Only reliably susceptible to vancomycin, daptomycin, and linezolid (essentially 100% susceptibility)1
- Next-best oral option is tetracycline, but only has 35% susceptibility, or co-trimoxazole (similar susceptibility)
- Other options include quinupristin-dalfopristin (100%), aminoglycosides (93%), and rifampin (85%)
References
- ^ Alefiya Neemuchwala, Deidre Soares, Vithusha Ravirajan, Alex Marchand-Austin, Julianne V. Kus, Samir N. Patel. In VitroAntibiotic Susceptibility Pattern of Non-diphtheriae CorynebacteriumIsolates in Ontario, Canada, from 2011 to 2016. Antimicrobial Agents and Chemotherapy. 2018;62(4). doi:10.1128/aac.01776-17.
